Drugs /

digoxin

Back to Drugs List

Overview

Generic Name(s):
digoxin
Trade Name(s):
Lanoxin and Cardiogoxin
NCI Definition [1]:
A cardiac glycoside. Digoxin inhibits the sodium potassium adenosine triphosphatase (ATPase) pump, thereby increasing intracellular calcium and enhancing cardiac contractility. This agent also acts directly on the atrioventricular node to suppress conduction, thereby slowing conduction velocity. Apparently due to its effects on intracellular calcium concentrations, digoxin induces apoptosis of tumor cells via a pathway involving mitochondrial cytochrome c and caspases 8 and 3. (NCI04)

Clinical Trials

View Clinical Trials for digoxin

Digoxin has been investigated in 4 clinical trials, of which 3 are open and 1 is closed. Of the trials investigating digoxin, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (1 open).

CDKN2A Overexpression, Complex karyotype, and HPV Positive are the most frequent biomarker inclusion criteria for digoxin clinical trials.

Malignant solid tumor, head and neck squamous cell carcinoma, and myelodysplastic syndromes are the most common diseases being investigated in digoxin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Digoxin
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Digoxin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating digoxin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
digoxin (substance), 4-[(3s,5r,8r,9s,10s,12r,13s,14s)-3-[(2s,4s,5r,6r)-5-[(2s,4s,5r,6r)-5-[(2s,4s,5r,6r)-4,5-dihydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-5h-furan-2-one, glaxo wellcome brand of digoxin, virco brand of digoxin, digossina, digoxin, lanoxin-pg, card-20(22)-enolide, 3-((o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)-, Lanoxin, digoxin, digoxigenin-tridigitoxosid, Cardiogoxin, 3beta,12beta,14-trihydroxy-5beta,14beta-card-20(22)-enolid-3-tridigitoxosid, 12beta-hydroxydigitoxin, digoxina, glaxosmithkline brand 1 of digoxin, digoxin (product), digoxine, lenoxin, 12β-hydroxydigitoxin, digoxin product, digoxin [chemical/ingredient], digoxinum, lanoxin pg
NCIT ID [1]:
C28990
SNOMED ID [1]:
F-61BBB

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.